Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival

Cancer

Volumn 115, Issue 15, 2009, Pages 3437-3445

  Akaza, Hideyuki ^a   Hinotsu, Shiro ^b   Usami, Michiyuki ^c   Arai, Yoichi ^d   Kanetake, Hiroshi ^e   Naito, Seiji ^f   Hirao, Yoshihiko ^g  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bicalutamide; Clinical trial; Combined androgen blockade; Deferred combined androgen blockade; Immediate combined androgen blockade; Luteinizing hormone releasing hormone agonist; Prostate cancer; Survival

Indexed keywords

BICALUTAMIDE; GOSERELIN; LEUPRIN; LEUPRORELIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR LOCALIZATION;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TOSYL COMPOUNDS;

EID: 68149098902     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24395     Document Type: Article

References (24)

1. Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171:1141-1147.
2. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439.
3. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491-1498.
4. Schellhammer PF, Sharifi R, Block NL, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Urology. 1997;50:330-336.
5. Fourcade R-O, McLeod D. Tolerability of antiandrogens in the treatment of prostate cancer. UroOncology. 2004;4:5-13.
6. Klotz L, Schellhammer P, Carroll K. A re-assessment of the role of combined androgen blockade for advanced prostate cancer. BJU Int. 2004;93:1177-1182.
7. Rothmann M, Li N, Chen G, et al. Design and analysis of non-inferiority mortality trials in oncology. Stat Med. 2003;22:239-264.
8. Akaza H, Yamaguchi A, Matsuda T, et al. Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol. 2004;34:20-28.
9. Usami M, Akaza H, Arai Y, et al. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis. 2007;10:194-201.
10. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2007 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25:1596-1605.
11. Akaza H, Arai Y, Kanetake H, et al. Efficacy of combined androgen blockade (CAB) therapy in stage C prostate cancer: exploratory analyses based on results of a double-blind, randomized, placebo-controlled phase III study of bicalutamide, 07 update. Available at: http://www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Virtual+Meeting?&vmview=vm-session- presentations-view&confID=47&sessionID=358. Accessed on June 5, 2009.
12. Japanese Urological Association and the Japanese Society of Pathology. General rule for clinical and pathological studies on prostatic cancer. 2nd edition. Tokyo: Kanehara. 1992.
13. Kotake T, Usami M, Isaka S, et al. [Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer]. Hinyokika Kiyo. 1996;42:157-168.
14. Kotake T, Akaza H, Usami M. Preliminary trial for clinical phase III study of Casodex-combination therapy with LH-RH agonist for prostate cancer. J N Remed Clin. 1999;48:1512-1533.
15. Akaza H. Current status and prospects of androgen depletion therapy for prostate cancer. Best Pract Res Clin Endocrinol Metab. 2008;22:293-302.
16. Sylvester RJ, Denis L, de Voogt H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. Eur Urol. 1998;33:134-143.
17. Kwak C, Jeong SJ, Park MS, et al. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol. 2002;168:995-1000.
18. Altwein JE, Schmidt A. Prostate-specific antigen dynamics predict risk of progression in advanced prostate cancer treated with bicalutamide plus castration. Urol Int. 2002;68:220-225.
19. Lukka H, Waldron T, Klotz L, et al. Maximal androgen blockade for the treatment of metastatic prostate cancer - a systematic review. Curr Oncol. 2006;13:81-93.
20. Hinotsu A, Niimi M, Akaza H, et al. [Development of Japanese version of QOL questionnaire for bladder and prostate cancer patients using FACT-Bl and P: pilot study]. Gan To Kagaku Ryoho. 1999;26:657-666.
21. Arai Y, Akaza H, Deguchi T, et al. Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study. J Cancer Res Clin Oncol. 2008;134:1385-1396.
22. Nishimura S, Arai Y, Usami M, et al. [Cost-effectiveness analysis of maximum androgen blockade for Japanese men with advanced prostate cancer]. Gan To Kagaku Ryoho. 2007;34:589-595.
23. Ramsey S, Veenstra D, Clarke L, et al. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology. 2005;66:835-839.
24. Penson DF, Ramsey S, Veenstra D, et al. The cost-effectiveness of combined androgen blockade with bicalutamide and LHRH agonist in men with metastatic prostate cancer. J Urol. 2005;174:547-552.